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12/05 to assess the number of c-DLI administered and the effect
of c-DLI on chimerism. Results: Of 135 allo-BMT, 29 DLI
were administered to 21 pts (median 1 DLI/pt, maximum, 3), 19
of which were c-DLI and 13 of which were for mini-allo-BMT.
A median of 10.5  106 CD3 T cells /kg pt weight (range 5 -
108  106) was administered. No unexpected infusion-related
toxicities or adverse events were encountered. Eight pts were
unevaluable for response, due to full donor chimerism at DLI
(4) or insufﬁcient data after DLI (4). Ten pts received 11 c-DLI
after min-allo-BMT to improve chimerism (4 NHL; 3 CLL; 2
Acute Leukemia; 1 MM). There were 6 responses in T cell
chimerism ( 5% increase) among 5 pts (4 NHL; 1 CLL), 2 to
full donor chimerism (2 NHL). The mean increase in chimerism
after all c-DLIs was 16% (0 - 50) and among responders the
mean increase in T cell chimerism was 24.5% and required a
mean 64 days (range 14 – 130 days). Four of 5 responders were
in CR before c-DLI and remained in CR, while 4 of 5 non-
responders had evidence of disease before and/or after c-DLI
(NS by Chi square). Fifteen pts received 21 c-DLI due to
persistent or recurrent disease (5 AML, 3 CLL, 3 lymphoma, 1
each CML, MM, MDS, Breast). Two pts were not evaluable for
response due to death within 30 days. Three pts had CRs
attributable, at least in part, to DLI (1 each AML, CML, MM).
Conclusions: Prospectively cryopreserved CD3 donor T cells
from mobilized PBSC are frequently employed for DLI after
mini-allo-BMT. Thawed c-DLI are readily available when
needed and are not associated with unexpected infusion toxicity.
C-DLI are frequently effective in improving donor chimerism
post BMT, however a prospective comparison of fresh vs c-DLI
will be required to assess comparative efﬁcacy.
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Thymoglobulin (rabbit anti-thymocyte globulin) is a potent T
cell-depleting agent in-vivo. Nevertheless, its speciﬁc effect on
T cells remains yet to be fully understood. When tested in-vitro
at doses  500 	g/ml thymoglobulin completely depletes T
cells. However, since thymoglobulin level in the serum of
treated patients is consistent with a 100 	g/ml concentration
in-vitro, we tested this dose in culture with puriﬁed T cells
alone, or with allogeneic antigen presenting cells (APCs). Com-
plement and 10% human serum were present in culture media.
In 12-days long kinetics experiments, stimulation with thymo-
globulin on d0, or d0 and d3, or d0, d3 and d6, induced T cell
proliferation, measured by 3H-thymidine uptake, with peaks on
d 4-5. Thymoglobulin also increased T cell responses when
added in primary allogeneic mixed leukocyte culture (MLC). T
cells pretreated with thymoglobulin for 3 d prior to MLC were
hyporesponsive to alloantigen in secondary MLC and did not
show cytotoxic T lymphocyte (CTL) activity, measured by
51Chromium release assay, while proliferated in response to
restimulation with thymoglobulin. Supernatants of MLC with
responder cells pretreated with thymoglobulin for 3 d contained
high levels of IL-13 and IL-5, as opposed to control experiments
with responders pretreated with PHA that showed high levels of
IFN and TNF
. Since after MLC with responders pretreated
with thymoglobulin 90% of T cells were
CD4CD25CD27 we tested the effect of thymoglobulin on
immunomagnetically isolated CD4CD25 (regulatory T
cells, Tregs) or CD4CD25- cells. After 5 d of culture with
thymoglobulin only CD4CD25- cells had proliferated and
both cell subsets expressed CD25, CTLA4, CD62L and GITR.
However, only thymoglobulin-treated CD4CD25 cell ex-
pressed FoxP3 and suppressed T cell alloreactivity when added
to a 3rd party MLC (4227% inhibition). In conclusion, since
we demonstrate that thymoglobulin initially drives T cell allo-
reactivity to Th2-type responses and preserves Tregs immuno-
suppressive activity, these ﬁndings may prompt new studies in
the prevention or treatment of acute GVHD.
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STEM CELL TRANSPLANTATION (SCT) WITH AND WITHOUT CONDI-
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SINGLE CENTER 25 YEAR EXPERIENCE
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Advances in SCT over the past 2 decades have expanded the
spectrum of PID for which this form of curative therapy has
been utilized. Failed, delayed and loss of donor engraftment and
immune function have emerged as signiﬁcant long-term prob-
lems in children with PID. We report the outcomes of condi-
tioned (COND) and non-conditioned (UNCOND) SCT regi-
mens in PID including: several forms of severe combined
immune deﬁciency (SCID), and non-SCID conditions (Wis-
kott-Aldrich syndrome (WAS), chronic granulomatous disease
(CGD), and Omenn syndrome) over the past 25 years. The
majority of transplants in UNCOND SCID and all UNCOND
non-SCID subjects were performed prior to 1999, utilized T
cell depleted bone marrow from related donors, and did not
include GVHD prophylaxis. The majority of transplants in
COND SCID and all COND non-SCID patients were per-
formed in 1999 or later, utilized bone marrow from matched
unrelated and related donors and CD34 selection of apheresed
mobilized stem cells from mismatched related donors. Prophy-
laxis for GVHD was utilized in all recipients of unselected
marrow and in recipients of CD34 selected stem cell products
with 5  104 T cells/kg. A total of 55 patients received 75
transplants with overall survivals of 64% and 82% in UN-
COND and COND patients respectively. Overall survival in 26
UNCOND SCID patients with related donors was 65% vs 80%
in 10 COND SCID patients. Four of 7 UNCOND non-SCID
patients survived vs. 7 of 8 COND non-SCID patients. Among
SCID survivors, 7, 3, and 1 COND patients and 13, 3, and 1
UNCOND patients received 1, 2, and 3 or more transplants
respectively. Among non-SCID survivors all 4 UNCOND and
6 of 7 COND patients received only 1 transplant. Feeding
problems and failure to thrive occurred frequently in SCID
patients prior to transplantation. Signiﬁcant pre transplant pul-
monary disease adversely affected survival in both COND and
UNCOND patients. Fatal post transplant EBV driven lympho-
proliferation was seen in only 1 patient, following an UN-
COND, T cell depleted bone marrow transplant from a hap-
loidentical, EBV sibling. In COND patients, serious post
transplant infections were related to central venous catheters,
and preexisting pulmonary or GI infection. Our experience
suggests that conditioning for SCID and non-SCID children
with severe PID results in excellent survival and may prove to
offer better long term engraftment and immune recovery.
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NK cells are characterized by absent CD3 and expression of
CD56 and are classiﬁed into CD56dim (90%) that are primarily
cytotoxic, and CD56bright that secrete cytokines (Shankaran et al
Nature 2001). NK subsets carry out their respective functions
based on their repertoire of NK receptors (NKRs) (Moretta et al
Annu Rev Immunol 2001). Despite an immaturity in CB T-cell
immunity, there is a similar leukemic relapse rate following UCBT
vs. UBMT (Cairo et al Blood 1997). Unlike PB NK subsets, there
is little information regarding CB NK subset function and NKR
expression. We compared PB vs. CB NK subset NKR expression
and protein expression. PB and CB cells were positively selected
for CD56 using magnetic beads (Miltenyi) and sorted into CD3
-
/
CD56bright and CD3-/CD56dim and NKR expression measured
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